Tech Company Financing Transactions
Violet Therapeutics Funding Round
Dementia Discovery Fund, UTEC and Mass General Brigham Ventures participated in a $10.6 million Seed funding round for Violet Therapeutics. The round was announced by the company on 5/31/2023.
Transaction Overview
Company Name
Announced On
5/31/2023
Transaction Type
Venture Equity
Amount
$10,600,000
Round
Seed
Investors
Dementia Discovery Fund (Lead Investor)
UTEC (Lead Investor)
Proceeds Purpose
Violet's initial drug discovery programs will focus on diseases affecting the Central Nervous System (CNS)."
Company Information
Company Status
Private & Independent
Industry
FinTech
Mailing Address
Undisclosed
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Violet Therapeutics is a pre-clinical stage company leveraging a first-in-class platforms to identify, map and mine the cellular connectome at scale. Violet's drug discovery programs are focused on CNS diseases enabled by the novel targets elucidated by their platforms. Violet was co-founded in 2021 by Mass General Brigham Ventures and scientists from Brigham & Women's Hospital.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Meredith Fisher
Browse more venture capital transactions:
Prev: 5/31/2023: Magic venture capital transaction
Next: 5/31/2023: LinusBio venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs